e-Therapeutics plc RNAi Platform Characterisation Results (2014Q)
26 Octubre 2021 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 2014Q
e-Therapeutics plc
26 October 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
RNAi Platform Characterisation Results
Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX;
OTCQX: ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics, today
announces the results of the Company's RNAi platform
characterisation studies.
Highlights
- RNAi platform benchmarking studies successfully completed
- Equivalent performance to leading competitor platforms
- Excellent and comparable safety profile seen in lead designs
- Consistent translation from in vitro to rodent and non-human primates (NHP)
- Additional six new patent applications filed to protect
innovation bringing to a total of eleven
On 1 February 2021, the Company announced the commencement of
multiple in vitro and in vivo studies to test newly designed small
interfering RNA ("siRNA") delivery moieties (GalNAc conjugates) and
novel RNA stabilisation chemistries. Three gene targets expressed
in hepatocytes (liver cells) were selected for benchmarking and
eight different GalNAc-siRNA construct designs were tested per
target.
The Company is now pleased to announce that it has successfully
established two different GalNAc-siRNA construct designs that have
shown at least equivalent performance in terms of potency, target
gene silencing and duration of action (up to three months) against
the best competitor data in the same targets. Benchmarking studies
included one approved RNAi drug and one currently in
registration.
To this end, on 11 October 2021 the Company announced that five
new patent applications had been filed to protect these novel
construct designs and a further six new patent applications have
now also been filed. The relevant summary dataset will be presented
at the Company's R&D Day in 2022 and headline non-human primate
data can be found in the interim results presentation at
http://www.rns-pdf.londonstockexchange.com/rns/2014Q_2-2021-10-25.pdf
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented: " These results are a crucial step forward for the
Company. We set a very high hurdle to benchmark our platform
against leading peer platforms and we are now confident that our
proprietary GalNAc-siRNA technology is competitive, having shown
equivalent performance. In the space of nine months, e-therapeutics
has achieved what has taken the industry many years to achieve. The
Company is now in a position to execute on its ambition of
developing an in-house pipeline combining novel target ideas
generated using its computational biology platform, and RNAi as a
modality."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside information is now
considered to be in the public domain.
Enquiries :
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBCBDGIUDDGBU
(END) Dow Jones Newswires
October 26, 2021 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024